Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226821 · ClinicalTrials.gov registry record · Phase 4
Body Composition and Adipose Tissue in HIV
A Phase 4 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03226821: Clinical Trial Phase 4 study, sponsored by Columbia University.
NCT03226821 is a Phase 4 study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03226821, a Phase 4 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, 6 and 12 months after daily injections of tesamorelin 2 mg by subcutaneous injection.
Primary Outcome
Hepatic lipid content (percent) will be measured by abdominal magnetic resonance imaging (MRI).
Interventions
- DRUG Tesamorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 4 |
Why NCT03226821 stopped before completion
NCT03226821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Tesamorelin is the first listed.
NCT03226821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03226821 about?
NCT03226821 is a clinical study titled "Body Composition and Adipose Tissue in HIV". In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with H...
What is the current status of trial NCT03226821?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-02-07. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT03226821?
The interventions under investigation include: Tesamorelin (DRUG).
Who is sponsoring clinical trial NCT03226821?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03226821's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI